These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 25188393

  • 1. Combined use of systemic agents for psoriasis: a systematic review.
    Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI.
    JAMA Dermatol; 2014 Nov; 150(11):1213-20. PubMed ID: 25188393
    [Abstract] [Full Text] [Related]

  • 2. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ, van de Kerkhof PC, de Jong EM.
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.
    Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, Thompson EH, Hooper M, Kricorian G.
    Br J Dermatol; 2012 Sep; 167(3):649-57. PubMed ID: 22533447
    [Abstract] [Full Text] [Related]

  • 4. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD.
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [Abstract] [Full Text] [Related]

  • 5. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH.
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [Abstract] [Full Text] [Related]

  • 6. Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence.
    Strohal R, Chimenti S, Vena GA, Girolomoni G.
    J Dermatolog Treat; 2013 Jun; 24(3):199-208. PubMed ID: 22812568
    [Abstract] [Full Text] [Related]

  • 7. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM.
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [Abstract] [Full Text] [Related]

  • 8. Etanercept for the treatment of rheumatoid arthritis.
    Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA.
    Cochrane Database Syst Rev; 2013 May 31; 2013(5):CD004525. PubMed ID: 23728649
    [Abstract] [Full Text] [Related]

  • 9. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis.
    Yamauchi PS, Lowe NJ.
    Int J Dermatol; 2008 Feb 31; 47(2):202-4. PubMed ID: 18211500
    [Abstract] [Full Text] [Related]

  • 10. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).
    Strohal R, Puig L, Chouela E, Tsai TF, Melin J, Freundlich B, Molta CT, Fuiman J, Pedersen R, Robertson D.
    J Dermatolog Treat; 2013 Jun 31; 24(3):169-78. PubMed ID: 22251226
    [Abstract] [Full Text] [Related]

  • 11. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH.
    Br J Dermatol; 2009 Jun 31; 160(6):1264-72. PubMed ID: 19120346
    [Abstract] [Full Text] [Related]

  • 12. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.
    Zachariae C, Mørk NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL, Johannesson A, Claréus B, Skov L, Mørk G, Walker S, Qvitzau S.
    Acta Derm Venereol; 2008 Jun 31; 88(5):495-501. PubMed ID: 18779890
    [Abstract] [Full Text] [Related]

  • 13. [Biologics in the treatment of psoriasis].
    Dissemond J, Grabbe S.
    MMW Fortschr Med; 2006 Sep 21; 148(38):42-4. PubMed ID: 17036963
    [Abstract] [Full Text] [Related]

  • 14. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.
    JAMA Dermatol; 2015 Apr 21; 151(4):432-8. PubMed ID: 25517130
    [Abstract] [Full Text] [Related]

  • 15. Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence.
    Foley PA, Quirk C, Sullivan JR, Dolianitis C, Hack SP, Thirunavukkarasu K, Cooper AJ.
    J Eur Acad Dermatol Venereol; 2010 Oct 21; 24(10):1135-43. PubMed ID: 20337816
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.
    Br J Dermatol; 2008 Aug 21; 159(2):274-85. PubMed ID: 18547300
    [Abstract] [Full Text] [Related]

  • 18. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
    Bronckers IMGJ, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E, Philipp S, Szalai Z, Vleugels RA, Holland K, Murphy R, Baselga E, Cordoro K, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Paller AS, Psoriasis Investigator Group (PsIG) of the Pediatric Dermatology Research Alliance and the European Working Group on Pediatric Psoriasis (EWGPP).
    JAMA Dermatol; 2017 Nov 01; 153(11):1147-1157. PubMed ID: 28903160
    [Abstract] [Full Text] [Related]

  • 19. Puerto Rico psoriasis study group: efficacy and safety of etanercept.
    González-Chavez JR, Berlingeri-Ramos AC, Sánchez Casiano MA.
    J Drugs Dermatol; 2005 Nov 01; 4(6):735-9. PubMed ID: 16302559
    [Abstract] [Full Text] [Related]

  • 20. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks.
    Gambichler T, Tigges C, Scola N, Weber J, Skrygan M, Bechara FG, Altmeyer P, Kreuter A.
    Br J Dermatol; 2011 Jun 01; 164(6):1383-6. PubMed ID: 21466532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.